A systems approach to designing next generation vaccines: Combining α-galactose modified antigens with nanoparticle platforms

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Phanse, Yashdeep ^a   Carrillo Conde, Brenda R ^b   Ramer Tait, Amanda E ^a,d   Broderick, Scott ^b   Kong, Chang Sun ^b   Rajan, Krishna ^b   Flick, Ramon ^c   Mandell, Robert B ^c   Narasimhan, Balaji ^b   Wannemuehler, Michael J ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b Iowa State University   (United States)

^c BioProtection Systems Corporation   (United States)

^d UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ANTIGEN; EPITOPE; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; PEPTIDE; VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CHEMISTRY; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; SYSTEMS BIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ALPHA-GALACTOSIDASE; ANTIGEN-PRESENTING CELLS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; HUMANS; IMMUNITY, INNATE; NANOPARTICLES; PEPTIDES; SYSTEMS BIOLOGY; VACCINES;

EID: 84892879661     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03775     Document Type: Article

References (59)

1. Wilson-Welder, J. H. et al. : Vaccine adjuvants: Current challenges and future approaches. J Pharm Sci 98, 1278-1316 (2009).
2. Feng, L. et al. : Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Cont Rel 112, 35-42 (2006).
3. Phanse, Y. et al. : Functionalization of polyanhydride microparticles with dimannose influences uptake by and intracellular fate within dendritic cells. Acta Biomater 9, 8902-8909 (2013).
4. Petersen, L. K., Phanse, Y., Ramer-Tait, A. E., Wannemuehler, M. J. & Narasimhan, B. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. Mol Pharm 9, 874-882 (2012).
5. Carrillo-Conde, B. et al. : Amphipilic polyanhydrides for stabilization of Yersinia pestis antigens. Acta Biomater 6, 3110-3119 (2010).
6. Carrillo-Conde, B. et al. :Mannose-functionalized ''pathogen-like'' polyanhydride nanoparticles target C-Type lectin receptors on dendritic cells. Mol Pharm 8, 1877-1886 (2011).
7. Petersen, L. K. et al. : Activation of innate immune responses in a pathogenmimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 32, 6815-6822 (2011).
8. Torres, M. P., Determan, A. S., Anderson, G. L., Mallapragada, S. K. & Narasimhan, B. Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 28, 108-116 (2006).
9. Torres, M. P. et al. : Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater 7, 2857-2864 (2011).
10. Ulery, B. D. et al. : Polymer chemistry influences monocytic uptake of polyanhydride nanospheres. Pharm Res 26, 683-690 (2008).
11. Ulery, B. D. et al. : Design of protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 6, e17642 (2010).
12. Ulery, B. D. et al. : Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci Rep 1, 198 (2011).
13. Anderson, G. W.J., Heath, D. G., Bolt, C. R., Welkos, S. L. & Friedlander, A. M. Short- and long-Term efficacy of sinlge-dose subunit vaccines agaisnt Yersinia pestis in mice. Am J Trop Med Hyg 58, 793-799 (1998). (Pubitemid 28307401)
14. Galili, U., Rachmilewitz, E. A., Peleg, A. & Flechner, I. A unique natural human IgG antibody with anti-A-Galactosyl specificity. J Exp Med 160, 1519-1531 (1984). (Pubitemid 15220780)
15. Galili, U. et al. : Evolution and pathophysiology of the human natural anti-A-Galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 15, 155-171 (1993). (Pubitemid 23281024)
16. Abdel-Motal, U. M., Guay, H. M., Wigglesworth, K., Welsh, R. M. & Galili, U. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J Virol 81, 9131-9141 (2007). (Pubitemid 47311456)
17. Abdel-Motal, U. M., Wigglesworth, K. & Galili, U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 27, 3072-3082 (2009).
18. Abdel-Motal, U. M. et al. : Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alphagal epitopes. Vaccine 28, 1758-1765 (2010).
19. Benatuil, L. et al. : The influence of natural antibody specificity on antigen immunogenicity. Eur J of Immunol 35, 2638-2647 (2005). (Pubitemid 41404047)
20. Mandell, R. B. et al. : The aGal HyperAcuteH technology: Enhancing immunogenicity of antiviral vaccines by exploiting the natural aGal-mediated zoonotic blockade. Zoonoses Public Hlth 56, 407-428 (2008).
21. Airhart, C. L. et al. : Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine. Vaccine 26, 5554-5561 (2008).
22. Elvin, S. J. et al. : Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine 24, 4433-4439 (2006).
23. Xiao, X. et al. : Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model. PLoS One 5, e13047 (2010).
24. Chiuchiolo, M. J. et al. : Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 194, 1249-1257 (2006). (Pubitemid 44630970)
25. Do, Y. et al. : Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol 40, 2791-2796 (2010).
26. Lee, L. H., Frasch, C. E., Falk, L. A., Klein, D. L. & Deal, C. D. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 21, 2190-2196 (2003).
27. Philipovskiy, A. V. & Smiley, S. T. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun 75, 878-885 (2007). (Pubitemid 46203452)
28. Smiley, S. T. Cell-mediated defense against Yersinia pestis infection. Adv Exp Med Biol 603, 376-386 (2007).
29. Gourley, T. S., Wherry, E. J., Masopust, D. & Ahmed, R. Generation and maintenance of immunological memory. Semin Immunol 16, 323-333 (2004). (Pubitemid 39451802)
30. Sallusto, F. & Lanzavecchia, A. Heterogeneity of CD41 memory T cells: Functional modules for tailored immunity. Eur J Immunol 39, 2076-2082 (2009).
31. Hill, J., Leary, S. E.C., Griffin, K. T.,Williamson, E. D. & Tiiball, R. W. Regions of Yersinia pestis V antigen that contribute to protection against plague idenfitied by passive and active immunization. Infect Immun 65, 4476-4482 (1997). (Pubitemid 27463214)
32. Motin, V. L., Nakajima, R., Smirnov, G. B. & Brubaker, R. Passive immunity to Yersinia mediated by anti-recombinantV antigen and protein A-V antigen fusion peptide. Infect Immun 62, 4192-4201 (1994). (Pubitemid 24301942)
33. Zepp, F. Principles of vacine design-Lessons from nature. Vaccine 28, C14-24 (2010).
34. Williamson, E. D. et al. : Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 14, 1613-1619 (1996). (Pubitemid 27041912)
35. Galili, U. et al. : Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Vaccine 14, 321-328 (1996). (Pubitemid 26126436)
36. Gonzalez, S. F., Pitcher, L. A., Mempel, T., Schuerpf, F. & Carroll, M. C. B cell acquisition of antigen in vivo. Curr Opin Immunol 21, 251-257 (2009).
37. Heesters, B. A. et al. : Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 38, 1164-1175 (2013).
38. Cherukuri, A., Cheng, P. C. & Pierce, S. K. The role of the CD19/CD21 complex in B cell processing and presentation of complement-Tagged antigens. J Immunol 167 (2001).
39. Goins, C. L., Chappell, C. P., Shashidharamurthy, R., Selvaraj, P. & Jacob, J. Immune complex-mediated enhancement of secondary antibody responses. J Immunol 184, 6293-6298 (2010).
40. Brady, L. J. Antibody-mediated immunomodulation: A strategy to improve host responses agaisnt microbial antigens. Infect Immun 73, 671-678 (2005). (Pubitemid 40165721)
41. Kunkl, A. & Klaus, G. G. The generation of memory cells, IV. Immunization with antigen-Antibody complexes accelerates the development of B-memory cells, the formation of germinal centres and the maturation of antibody affinity in the secondary response. Immunol 43, 371-378 (1981). (Pubitemid 11031816)
42. Donius, L. R.,Handy, J. M.,Weis, J. J. & Weis, J.H. Optimal germinal center B cell activation and T-dependent antibody responses require expression of the mouse complement receptor Cr1. J Immunol 191, 434-447 (2013).
43. Roozendaal, R. & Carroll, M. C. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 219, 157-166 (2007). (Pubitemid 47390008)
44. Galili, U., Wigglesworth, K. & Abdel-Motal, U. M. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol 178, 4676-4687 (2007). (Pubitemid 46501667)
45. Galili, U. a1,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates. Xenotransplantation 20, 267-276 (2013).
46. Eyles, J. E. et al. : Immunisation against plague by transcutaneous and intradermal application of subunit antigens. Vaccine 22, 4365-4373 (2004). (Pubitemid 39330362)
47. Huntimer, L. et al. : Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platforms for vaccine delivery. Adv Health Mater 2, 369-378 (2013).
48. Rafit, K., Bergtold, A. & Clynes, R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110, 71-79 (2002). (Pubitemid 34743467)
49. Powell, B. S. et al. : Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21, 1490-1510 (2005). (Pubitemid 41443005)
50. Pullen, J. K., Anderson, G.W., Welkos, S. L. & Friedlander, A. M. Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes. Infect Immun 66, 521-527 (1998). (Pubitemid 28074191)
51. Titball, R. W. & Williamson, E. D. Vaccination against bubonic and pneumonic plague. Vaccine 19, 4175-4184 (2001). (Pubitemid 32703638)
52. Williamson, E. D. et al. : Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73, 3598-3608 (2005). (Pubitemid 40745904)
53. Vernazza, C. et al. : Small protective fragments of the Yersinia pestis V antigen. Vaccine 27, 2775-2780 (2009).
54. Quenee, L. E. et al. : Amino acid residues 196-225 of LcrV represent a plague protective epitope. Vaccine 28, 1870-1876 (2010).
55. Du, S. X. et al. : A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. PLoS One 6, e20927 (2011).
56. Thakur, A., Pedersen, L. E. & Jungersen, G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30, 4907-492 (2012).
57. Fletcher, H. A. Correlates of immune protection from tuberculosis. Curr MolMed 7, 319-325 (2007). (Pubitemid 46767789)
58. Naicker, K. P., Li, H., Heredia, A., Song, H. & Wang, L. X. Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIVimmunotargeting. Org Biomol Chem 2, 660-664 (2004).
59. Ramer, A. E., Vanloubbeeck, Y. F. & Jones, D. E. Antigen-responsive CD41 T cells from C3H mice chronically infected with Leishmania amazonensis are impaired in the transition to an effector phenotype. Infect Immun 74, 1547-1554 (2006). (Pubitemid 43346787)